Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Hepatoma Res 2020;6:11. 10.20517/2394-5079.2019.51 © The Author(s) 2020.
Open Access Original Article

Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series

1Johns Hopkins University School of Medicine, Division of Gastroenterology and Hepatology-Transplant Hepatology, Baltimore, MD 21205, USA.

2Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA.

3Johns Hopkins University School of Medicine, Division of Transplant Surgery, Baltimore, MD 21205, USA.

Correspondence Address: Dr. Ahmet Gurakar, Division of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, 720 Rutland Avenue Ross Research Building, Suite 918 Baltimore, MD 21205, USA. E-mail:

    Views:1256 |  Downloads:393 |  Cited:0 |  Comments:1 |  :5
    Science Editor: Guang-Wen Cao | Copy Editor: Jing-Wen Zhang | Production Editor: Tian Zhang

    © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (, which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.


    Aim: We aimed to study the clinical and pathological characteristics of liver transplant recipients with hepatocellular carcinoma recurrence.

    Methods: We reviewed the data for 26 patients who had tumor recurrence after deceased donor liver transplant for hepatocellular carcinoma at the Johns Hopkins Hospital from January 2005 to December 2015.

    Results: In total, 88% of recipients were males. The mean age was 59 years. On explant, poor differentiation was detected in 43%, while 73% had microvascular invasion. Overall, 62% were diagnosed to be outside of Milan criteria. Out of these, 15% met the criteria for downstaging. Twenty (77%) patients had pre-transplant alpha fetoprotein levels ≥ 20 ng/mL. In 54% of patients, the location of hepatocellular carcinoma (HCC) recurrence was extrahepatic, followed by intrahepatic in 31% and both intra- and extrahepatic in 15%. The post-transplant tumor recurrence was diagnosed at a mean of 427 days (range 34-1502). Fifty percent of HCC recurrences were diagnosed within one year following liver transplant. Twenty (77%) patients received treatment for their recurrent HCC: external radiation (n = 10), surgical resections (n = 8; brain 4, spine 2, bone 1, and Whipple surgery 1), sorafenib (n = 7), locoregional therapy (n = 5). Overall, 24 out of 26 (92%) recipients died within four years after the transplant.

    Conclusion: HCC recurrence after liver transplant is infrequent. More than fifty percent of HCC recurrences following liver transplant are extrahepatic. Despite better recipient selection for liver transplant, the curative options are limited in recurrent cases and associated with extremely poor outcomes.


    Liver transplant (LT) has become the treatment of choice in patients with hepatocellular carcinoma (HCC) and cirrhosis who meet the Milan criteria (MC)[1]. Although additional extended criteria models have been proposed, HCC recurrence following LT remains an unfortunate incident associated with poor survival[2,3]. Tumor biology and alpha fetoprotein (AFP), as well as tumor size and number, have been proposed by various groups as other potentially relevant factors of tumor recurrence[4-6].

    Overall, two thirds (2/3) of patients, who develop recurrent HCC post-LT, present with extrahepatic recurrence[7,8]. The treatment of choice in post LT HCC recurrence is determined based on the site and the extent of the recurrence[8]. However, treatments are not standardized and mostly based on expert opinion and retrospective studies[9]. Surgical treatment options have been proposed with promising outcomes in selected patients[10,11]. Locoregional therapy options, transarterial chemoembolization, radiofrequency ablation, and stereotactic radiation are considered in selected cases[9].

    In a recent report, we published our experience in LT recipients with HCC at the Johns Hopkins University Comprehensive Liver Transplant Center[12]. As a follow-up study, we aimed to study the clinicopathological features and outcomes of 26 cases with HCC recurrence following LT. In addition, we evaluated the details on the outcomes and the application of different treatment modalities in this group.


    The study was approved by the institutional review board at the Johns Hopkins Hospital. HCC-related deceased donor LT recipients between January 2005 and December 2015 were evaluated. In total, 26 patients with post-LT HCC recurrence were identified among 165 recipients who were included in the study. All recipients were listed following a standard work up and discussion at the weekly selection meeting. They were within Milan criteria or downstaged into Milan criteria. The transplant was performed by piggyback technique. Postoperative HCC surveillance consisted of contrasted cross-sectional imaging with computerized tomography or magnetic resonance imaging with AFP every three months for the first year and every six months for the second and third years. There was no set therapeutic protocol for recurrence; treatment options were discussed in a multidisciplinary fashion. The Pre-LT AFP was obtained within the past three months prior to deceased donor liver transplantation (DDLT) and immediate post-LT AFP was obtained within three months post DDLT.

    Data on clinical, radiologic, pathology, HCC recurrence, and survival were collected from the records, reviewed, and analyzed. Explant pathologies were reviewed retrospectively, and the following tumor parameters were collected: size, number of lesions, microvascular invasion status, and differentiation. It was determined whether patients met the Milan or University of California San Francisco (UCSF) criteria based on the number and size of HCC lesions on explant pathology. The data collected for categorical variables were reported as percentages. Data for continuous variables were reported by the mean and standard deviation. Patient survivals were analyzed using Kaplan-Meier statistics. STATA V.13 (StataCorp college station, TX) was used to perform the statistical analyses.


    Patient characteristics

    Among the deceased donor LT recipients, HCC was the primary indication for transplantation varying from 21% to 53% of patients [Figure 1] according to the year. Clinical information on the 26 LT recipients with recurrent HCC is summarized in Table 1. Patients were predominantly male (88.5%) with a mean age of 59 years (range 47-72 years). The majority of recipients were white (n = 17, 65.4%), followed by African American (n = 7, 27.0%) and Asian (n = 2, 7.6%) ethnicities. Primary etiology of liver disease was chronic hepatitis C (positive hepatitis C antibody and/or hepatitis C RNA) in 13 patients (50%) and hepatitis C and alcoholic liver disease in 6 (23%) patients. Chronic hepatitis B (positive hepatitis B surface antigen and/or hepatitis B DNA) was seen in three patients (11.5%), followed by alcoholic liver disease (n = 2, 7.7%), and non-alcoholic fatty liver disease (n = 1, 3.9%).

    Figure 1. Overall, rate of deceased donor liver transplant for hepatocellular carcinoma indication at the Johns Hopkins Hospital from 2005 to 2015. HCC: hepatocellular carcinoma

    Table 1

    Characteristics of the study population

    Variablen = 26
    Clinical features
      Male sex, n (%)      23 (88.5%)
      Age (years)      58.9 (6.8)
      Ethnicity, n (%)
        White      17 (65.4%)
        African American      7 (27.0%)
        Asian      2 (7.6%)
        HCV      13 (50%)
        HBV      3 (11.5%)
        ALD      2 (7.7%)
        NAFLD      1 (3.9%)
        HCV/ALD      6 (23%)
        Other      1 (3.9%)
    Explant pathology
      Number of lesions, n (%)
        1      9 (34.6%)
        2      3 (11.5%)
        3      3 (11.5%)
        > 4      11 (42.4%)
      Largest lesion (cm)      4.3 (3.8)
      Tumor location, n (%)
        Right lobe      13 (50%)
        Left lobe      1 (3.9%)
        Multi-lobar      12 (46.1%)
      Tumor differentiation, n (%)
        Well      0 (0%)
        Moderate      14 (53.8%)
        Poor      11 (42.3%)
        Unknown      1 (3.9%)
      Microvascular invasion, n (%)
        Yes      19 (73.1%)
        No      6 (23%)
        Bile duct invasion      1 (3.9%)
      Total number of loco-regional therapies, n (%)
        0      9 (34.6%)
        1      9 (34.6%)
        2      5 (19.2%)
        > 2      3 (11.6%)
      Patients with viable tumor, n (%)
        Yes      25 (96.2%)
        No      1 (3.8%)
      Within Milan, n (%)
        Yes      10 (38.4%)
        No      16 (61.6%)
      Downstaged to Milan, n (%)      4 (15.4%)
      Within UCSF, n (%)
        Yes      11 (42.3%)
        No      15 (57.7%)
      Downstaged to UCSF, n (%)      3 (11.5%)
      Pre-LT AFP (ng/mL)      27,578 (133,183)
      Post-LT AFP (ng/mL)      23,586 (81,707)
      MELD      13(7)
      WBC (109/L)      6 (2.2)
      Hgb (g/dL)      12.9 (2.7)
      MCV (fL)      91(6)
      PLT (103/μL)      116(67)
      BUN (mg/dL)      15(6)
      Creatinine (mg/dL)      1.1 (0.6)
      TP (g/dL)      7.2 (0.8)
      Alb (g/dL)      3.6 (0.7)
      ALP (U/L)      141(58)
      AST (U/L)      109(167)
      ALT (U/L)      71(122)
      T.Bili (mg/dL)      2.2 (2.4)
      PT (sec)      14 (4.1)
      INR      1.3 (0.4)

    Laboratory results

    The average model for end-stage liver disease (MELD) score was 13, ranging from 6 to 35. Mean AFP was 27.6 ng/mL for pre-LT vs. 23.6 ng/mL for post-LT time periods [Tables 1 and 2]. Four patients had pre-LT AFP levels of > 1000 ng/mL. The other available laboratory results are summarized in Table 1.

    Table 2

    Alpha fetoprotein levels pre and post-liver transplant

    PatientPre-LT AFPInitial post-LT AFPAFP at recurrence
    1     9          7        2019
    2     28,139          365,210        NA
    3     135          4.1        15
    4     3.6          0.6        1.7
    5     27          3864        NA
    6     488          57        86
    7     22          2        26
    8     23          12        1416
    9     162          6.4        7
    10     169          682        3342
    11     34          3        389
    12     48          4        12
    13     323          76        157
    14     7          21        NA
    15     23          10        51
    16     4659          25,154        NA
    17     304          35        5.4
    18     3.3          4.3        210
    19     1707          100        47,304
    20     34          2        3.7
    21     680,000          217,576        120,848
    22     22          2        17
    23     4          2        NA
    24     207          317        40.9
    25     486          104        3677
    26     5.2          5.5        4


    Overall, nine (34.6%) patients were treated with mammalian target of rapamycin (mTOR) treatment with sirolimus in eight and everolimus in one patient. Seventeen patients received Tacrolimus-based therapy.

    Explant-pathology findings

    In the explant pathologies of LT recipients, 9 (34.6%) patients had only one lesion and 11 (42.4%) had 4 or more lesions. The average for the largest lesion size was 4.3 cm. In total, 12 patients (46.1%) had multi-lobar tumors and 13 (50%) had tumors that were located in the right lobe. Overall, 10 patients (38.4%) were within MC criteria and 11 patients (42.3%) were within UCSF criteria. Four patients (15.4%) were downstaged to MC with locoregional treatment. Seventeen (65.4%) patients underwent locoregional therapy before transplant. None of the tumors were well-differentiated. Overall, 14 (53.8%) patients had moderately differentiated HCC. Eleven (42.3%) patients had HCC with poor differentiation. Microvascular invasion was detected in 19 of the 26 cases (73.1%) while one patient had bile duct invasion only.

    Recurrence and survival

    The overall rate of HCC recurrence following LT in our series was 15%. The rate of HCC recurrence has improved over the years with a recurrence rate of 10% in 2015 [Figure 2]. Mean time for diagnosis of HCC recurrence after LT was 427 days, ranging from 34 to 1502 days. The site of HCC recurrence was intrahepatic in 8 (31%), extrahepatic in 14 (54%), and both intra- and extrahepatic in 4 (15%) patients. Overall, 31% of recipients had intrahepatic HCC recurrence following LT when compared to 69% with extrahepatic recurrence. Twenty-two percent of the patients who had extrahepatic involvement had concomitant liver involvement. The most common sites of extrahepatic involvement were the lungs (44.4%) and bones (44.4%) (spine, rib, pelvis, and humerus), followed by mediastinum (27.8%), brain (22.2%), portal lymph nodes (11.1%), gastro-hepatic ligament (5.6%), adrenal gland (5.6%), pleura (5.6%), and peritoneum (5.6%).

    Figure 2. Overall, per year rate of hepatocellular carcinoma recurrence in deceased donor liver transplant recipients at the Johns Hopkins Hospital from 2005 to 2015. HCC: hepatocellular carcinoma

    A range of different treatment modalities was used for recurrences [Table 3]. Six (21.4%) of the 26 patients were managed with supportive care. The remaining 20 cases received various treatment modalities including locoregional therapy (transarterial chemoembolization in 3, Y 90 in 1, and radiofrequency ablation in 1), external radiation in 10, and surgical resections in 8 (brain 4, spine 2, bone 1, and Whipple surgery in 1). Nine (32%) patients received combination therapies of the above-mentioned modalities. Seven patients (27%) received sorafenib. An additional two patients received chemotherapy regimens other than sorafenib [Table 3]. Recurrence-free survival and overall survival are shown in Figure 3. Patients who developed HCC recurrence following LT had an extremely poor overall survival (7.7%). In total, 19% of patients died within one year following LT. Overall, 24 out of 26 (92.3%) patients died throughout the four-year follow-up period. Timing of death relevant to the time of LT is shown in Table 3.

    Figure 3. Survival analysis for 26 liver transplant recipients with hepatocellular carcinoma recurrence: A: Kaplan-Meier curve for recurrence-free survival; B: Kaplan-Meier curve for overall survival

    Table 3

    Specific characteristics of the tumors, treatment, and outcomes

    PatientNumber of lesionsLargest lesion (cm)Within Milan criteriaDownstagedMVIDifferentiationDiagnosis of recurrence following LT (in days)Site of recurrenceSurvivalTime of death following LT (days)Treatment of recurrence
    15    4      No      NoYesModerate         984Gastro-hepatic ligament, mediastinalDied   1466Sorafenib
    21    8      No      YesYesPoor         314LiverDied   369Supportive care
    35    8.5      No      YesYesModerate         950BrainDied   1062Brain metastasis resection
    4Infiltrative    1.1      No      NoYesModerate         536LiverDied   780Y90
    51    1      Yes      NoNoModerate         80Porta-hepatisDied   366Chemotherapy with capecitabine
    61    7.5      No      NoYesPoor         102Perihilar, lungDied   222Supportive care
    7Infiltrative    2      No      NoYesPoor         224Brain, liver, adrenalDied   1459Brain metastasis resection and radiation, cryoablation of adrenal metastasis, Y90 in liver
    83    1      Yes      NoNoModerate         490Humerus, brainDied   663Bone resection and radiation, brain met resection
    98    4.3      No      NoYesPoor         291Ribs, spineDied   602Sorafenib
    Spine surgery and radiation
    102    1.5      Yes      NoNoModerate         94Portal nodes, mediastinal, lungDied   253Sorafenib, external radiation
    112    1.6      Yes      NoYesPoor         464Bone, lungDied   547Supportive care
    121    5      Yes      NoYes (bile duct)Poor         482Bile ductsDied   1131Whipple surgery, Sorafenib
    135    6      No      NoYesModerate         111Lung, peritoneal carcinomatosisDied   332Supportive care
    14Infiltrative    2.8      No      NoYesModerate         544Pelvic boneDied   1079External radiation, Sorafenib
    151    2.3      Yes      NoNoModerate         795SpineDied   1319Spine surgery and radiation
    161    7.2      No      NoYesPoor         93Pelvic bone, lungDied   493External radiation
    175    3.5      No      NoYesPoor         261LiverAlive   -TACE
    183    3.5      No      YesYesModerate         713Lung, liverDied   861TACE
    191    2.9      Yes      NoYesPoor         346LiverDied   407Supportive care
    201    2.8      Yes      NoYesModerate         1502LiverAlive   -RFA, TACE, Sorafenib
    21Infiltrative    19      No      NoYesPoor         78Lung, bone, liverDied   178Chemotherapy with Gemcitabine/Cisplatin, external radiation
    222    2.6      Yes      NoYesPoor         199LiverDied   260Supportive care
    235    2      No      NoNoModerate         594BrainDied   1156Brain metastasis resection
    243    7.5      No      YesYesModerate         147Mediastinal lymph nodes, pleuraDied   697Sorafenib
    25Infiltrative    4      No      NoYesModerate         34Spine, mediastinalDied   1065Spine radiation
    261    2.2      Yes      NoNoNo viable tissue         917Lung, mediastinalDied   1359External radiation


    In this series, we report a rate of 15% HCC recurrence following deceased donor LT at our transplant program. This rate is consistent with the literature report of 15%-20% post-LT HCC recurrence[13]. It is well known that the patients who are outside of MC prior to LT have higher rates of tumor recurrence following LT, compared to those within the MC[1]. Although all of the patients within our series were thought to be within MC radiographically prior to LT, according to radiology findings, only 34% were within the criteria by reviewing the explant. When including an additional four (15%) patients who were downstaged, in total 49% were within MC based on pathology. This discrepancy between radiology and pathology has been previously described by other groups in the literature[13].

    Our sites of recurrence findings are very similar to the recent reports[8]. In a systematic review of post-LT HCC recurrence, extrahepatic site was the most common site of recurrence in 67% of cases, compared to intrahepatic in 33%[8]. The extrahepatic sites of involvement included: bone, pulmonary, adrenal, lymph nodes, and brain[8].

    Within our series, 54% of the HCC recurrences were diagnosed within 1 year post-OLT, while 81% and 96% of recurrences occurred within 2 and 3 years following OLT, respectively. The average time to HCC recurrence within our series was 427 days (range 34-1502 days). It is shown by others that early versus late recurrence is a predictor of post-LT survival[14]. The patients with early HCC recurrence, defined as recurrence within 24 months post-LT, have a worse prognosis[14]. There are a few potential theories for early HCC recurrence post-LT: (1) biologically rapid growing, aggressive tumors; (2) lack of high-quality pre-LT imaging or overlooking intra- or extrahepatic imaging[8]; (3) extrahepatic microscopic viable HCC cells that could not be detected by conventional imaging prior to LT; and (4) presence of circulating tumor cells that seed to other sites. The mechanism by which the late recurrence occurs is unclear[15]. Presence of pre-LT HCCs that are biologically slow growing, or development of de novo HCC recurrence in the liver allograft could be the cause. Within our series, we did not have any cases who had HCC recurrence that occurred or were diagnosed beyond five years following LT.

    The selection of an ideal treatment for post LT HCC recurrence is a matter of debate, and the evidence is mainly based on expert opinion and non-randomized cohort studies[9]. The treatment modality will vary based on the type of recurrence (intrahepatic versus extrahepatic), organ of involvement, and extent of involvement. This includes a wide range of surgical (intra- or extrahepatic resection and re-transplantation) and non-surgical treatments (locoregional therapies, sorafenib, other systemic chemotherapy, mTOR inhibitors, and best supportive care)[16].

    Surgical options including extrahepatic resection, liver graft resection, and liver re- transplant have also been considered for patients presenting with HCC recurrence. In 2004, the Mount Sinai group reported resection of the liver allograft in five out of 18 recipients with HCC recurrence[11]. The authors concluded that, in selected cases with recurrent intrahepatic-HCC, liver resection improved survival[11] Similarly, Kornberg et al.[10] reported that HCC recurrence should be treated surgically in eligible patients with good long-term outcomes. In multivariate analysis of post-LT HCC recurrence, late tumor recurrence (> 24 months) and surgical resection were the two independent predictors of survival[10]. A systematic review in 2015 reported that the surgical approach to localized intra- or extra-hepatic recurrences are uneventful and not associated with higher mortality[8]. Retransplantation for recurrent HCC is not a practical option[17] due to the higher risk of recurrence with a limited organ availability.

    Sorafenib, a multikinase inhibitor, has been approved as first-line treatment for the management of advanced-stage HCC following two clinical trials in 2008 and 2009[18,19]. In a multicenter phase 2, blinded placebo-controlled, clinical trial, the efficacy of sorafenib for preventing HCC recurrence post-LT in high-risk recipients is being actively investigated [ identifier (NCT number): NCT01624285]. There are currently no systemic therapies that have been shown to improve survival in HCC recurrence post-LT. Recently, other tyrosine kinase inhibitors were approved as first- or second-line treatment in HCC in the non-transplant setting[20]. The role of these agents as adjuvant therapy or post-LT HCC recurrence is unclear and deserves further investigation in the near future. Nivolumab, an anti-PD1 inhibitor, was recently approved for the treatment of HCC, as second line, in the non-transplant setting, with the objective response rate of 20%[21]. The role of immunotherapy among post-LT recipients with HCC has not been yet established. It is possible that the immunotherapy will affect the liver allograft leading to acute cellular rejection[22].

    Mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, has been shown to be upregulated in 40%-50% of HCCs. mTOR is involved in the regulation of cell metabolism and growth[23]. Therefore, various studies have suggested that mTOR inhibitors may have antineoplastic properties in HCC patients and mTOR inhibitors should be used after LT. In a meta-analysis of 2950 patients from five studies, sirolimus-based immunosuppression reduced the rate of tumor recurrence and improved overall survival[24].

    HCC recurrence following LT is an unfortunate event and associated with poor outcomes. In a recent meta-analysis, the median overall survival was 13 months following the diagnosis of HCC recurrence post-LT[8]. Herein, supportive care was associated with the lowest survival rate of 3.3 months[8]. There is no standardized protocol regarding the type and frequency of post-LT cross-sectional imaging in surveillance of HCC LT recipients. It is important to note that more than 50% of patients develop tumor recurrences that are outside of liver (extrahepatic), therefore imaging limited to the liver may not be sufficient for the diagnosis of majority of HCC recurrences. We also note that AFP is a useful marker in post-LT HCC surveillance only for high-AFP-secreting tumors. Four patients in our study had pre-AFP levels of > 1000 ng/mL. It is well known that patients with high AFP producing tumors have worse tumor biology and have worse outcomes[12,25]. HCC candidates need to have AFP of ≤ 1000 ng/mL to receive extra points to shorten the waiting period for liver transplantation[25]. The overall prognosis of HCC recurrence following LT is poor in the majority of cases and there are no available studies evaluating cost-effectiveness of surveillance protocols specific to this group of patients.

    In conclusion, HCC recurrence post liver transplant is an unfortunate event associated with extremely poor survival. The majority of the cases are early recurrence occurring 1-2 years following liver transplantation. More than 50% of HCC recurrences are extrahepatic. Therefore, post-liver transplant imaging confined to the liver may not be enough to detect all of the recurrences. In patients with AFP producing tumors, this marker may also be helpful to diagnose the HCC recurrence. There is no general consensus on the treatment for post liver transplant hepatocellular carcinoma recurrence. The current reports are mainly based on single-center retrospective experience.


    Authors’ contributions

    Acquisition of data, analysis and interpretation of data, drafting of the manuscript: Simsek C

    Interpretation of the data, Final Editing and Critical Review of the manuscript for important intellectual content: Kim A

    Acquisition of data, analysis and interpretation of data, drafting of the manuscript: Ma M

    Review of the data, drafting of the manuscript and editing: Danis N

    Analysis and interpretation of data, statistical analysis: Gurakar M

    Study concept and design, interpretation of data, critical revision manuscript for important intellectual content: Cameron AM

    Study concept and design, interpretation of data, critical revision of the manuscript for important intellectual content: Philosophe B

    Study concept and design, interpretation of data, statistical analysis, critical revision of the manuscript for important intellectual content: Garonzik-Wang J

    Study concept and design, critical revision of the manuscript for important intellectual content: Ottmann S

    Study concept and design, acquisition of data, drafting of the manuscript, analysis and interpretation of data, revision of the manuscript for important intellectual content study supervision: Gurakar A

    Study concept and design, acquisition of data, drafting of the manuscript, analysis and interpretation of data, critical revision of the manuscript for important intellectual content, study supervision: Saberi B

    Availability of data and materials

    Data source has been the Electronic Medical System. Please contact the corresponding author for unidentified data availability.

    Financial support and sponsorship

    This Research is partially supported by NIH Grants: R44 CA165312 - Development of a urine test for the early detection of liver cancer. U01 CA230690 - Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer.

    Conflicts of interest

    All authors declared that there are no conflicts of interest.

    Ethical approval and consent to participate

    This retrospective study was approved by Johns Hopkins IRB NA_00028034.

    Consent for publication

    Not applicable.


    © The Author(s) 2020.


    • 1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.

    • 2. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.

    • 3. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.

    • 4. Andreou A, Gul S, Pascher A, Schoning W, Al-Abadi H, et al. Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma. HPB (Oxford) 2015;17:168-75.

      DOIPubMed PMC
    • 5. Marshall AE, Rushbrook SM, Vowler SL, Palmer CR, Davies RJ, et al. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl 2010;16:279-88.

    • 6. Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S67-71.

      DOIPubMed PMC
    • 7. Fernandez-Sevilla E, Allard MA, Selten J, Golse N, Vibert E, et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection? Liver Transpl 2017;23:440-7.

    • 8. de’Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol 2015;21:11185-98.

      DOIPubMed PMC
    • 9. Chok K. Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol 2015;7:1142-8.

      DOIPubMed PMC
    • 10. Kornberg A, Kupper B, Tannapfel A, Katenkamp K, Thrum K, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010;36:275-80.

    • 11. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-40.

    • 12. Gurakar A, Ma M, Garonzik-Wang J, Kim A, Anders RA, et al. Clinicopathological distinction of low-AFP-secreting vs. high-AFP-secreting hepatocellular carcinomas. Ann Hepatol 2018;17:1052-66.

    • 13. Guerrero-Misas M, Rodriguez-Peralvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015;7:649-61.

      DOIPubMed PMC
    • 14. Chok KS, Chan SC, Cheung TT, Chan AC, Fan ST, et al. Late recurrence of hepatocellular carcinoma after liver transplantation. World J Surg 2011;35:2058-62.

      DOIPubMed PMC
    • 15. Zhang JA, Kwee SA, Wong LL. Late recurrence of hepatocellular carcinoma after liver transplantation. Hepatoma Res 2017;3:58-66.

      DOIPubMed PMC
    • 16. Rubin J, Ayoub N, Kaldas F, Saab S. Management of recurrent hepatocellular carcinoma in liver transplant recipients: a systematic review. Exp Clin Transplant 2012;10:531-43.

    • 17. Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol 2014;20:10223-37.

      DOIPubMed PMC
    • 18. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.

    • 19. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.

    • 20. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018;15:599-616.

    • 21. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.

    • 22. Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J 2018;6:970-3.

      DOIPubMed PMC
    • 23. Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 2014;60:855-65.

      DOIPubMed PMC
    • 24. Liang W, Wang D, Ling X, Kao AA, Kong Y, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18:62-9.

    • 25. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-fetoprotein decrease from > 1,000 to < 500 ng/mL in patients with hepatocellular carcinoma leads to improved posttransplant outcomes. Hepatology 2019;69:1193-205.


    Cite This Article

    Simsek C, Kim A, Ma M, Danis N, Gurakar M, Cameron AM, Philosophe B, Garonzik-Wang J, Ottmann S, Gurakar A, Saberi B. Recurrence of hepatocellular carcinoma following deceased donor liver transplantation: case series. Hepatoma Res 2020;6:11.



    Download and Bookmark


    Download PDF Add to Bookmark

    Share This Article

    Article Access Statistics

    Full-Text Views Each Month

    PDF Downloads Each Month


    Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at

    • Patricia Desmond   
      Dr. Riaria cured my herpes virus that have been in my body since two years, ever since then my life has been incomplete, I have used so many drugs that was prescribed to me by doctors, but it didn't cure my herpes virus, i was checking for solution on the internet then I miraculously came across Dr. Riaria the powerful herbalist that  can cure herpes infection, then I contacted him through his email, I explained everything to him and he prepared a herbal medicine and sent it to me through FedEx, which I took for 14 days with the instruction he gave me, and when I did a test in the hospital my result came out negative it was the happiest day of my life that am cure from HSV 2,  are you also suffering from same virus or another diseases you can simply contact him via email:  you can also call or WhatsApp him on: +2349134987375.  
      You can visit his website for more info: 

      24 Oct 2021 22:09


    Article Access Statistics

    • Viewed: 1256
    • Downloaded: 393
    • Cited: Crossref0

    Share This Article

    See Updates

    © 2016-2021 OAE Publishing Inc., except certain content provided by third parties